We are researching active substances such as emrusolmin (anle138b), which directly target the cause of the disease. These drugs should not only alleviate symptoms, but also halt the progression of the disease.<\/p>\n<\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/div>
<\/i><\/div><\/div>Our progress in research<\/h2><\/div><\/div><\/div>Our drug candidate emrusolmin (anle138b, TEV-56286) for MSA<\/h3><\/div>Before use on humans<\/h4><\/div>Extensive laboratory tests with world-leading scientists to understand the mechanisms of action<\/p>\n<\/div>
Phase 1<\/h3><\/div>Procedure<\/b><\/span><\/div>\n\n- Phase 1a<\/b>
<\/b><\/span><\/span>First application on healthy participants<\/span><\/li>\n- Phase 1b<\/span>
<\/span><\/b>First application on patients<\/span><\/li>\n- DDI study<\/span><\/span>
<\/span><\/b>Checking whether the drug interacts with other drugs<\/span><\/li>\n<\/ul>\nActive ingredient behavior in the body<\/b><\/p>\n\n- Oral ingestion, half-life of ~12 hours, food intake does not impair the exposure<\/li>\n
- Exposure: blood concentrations reach values that were effective in animal models<\/li>\n<\/ul>\n
Security
<\/b><\/p>\n\n- No pattern of drug-related side effects<\/span><\/li>\n
- No serious adverse events have occurred<\/span><\/li>\n<\/ul>\n<\/div>
Phase 2<\/h3><\/div>TOPAS-MSA study<\/span>
<\/b>(T<\/span>argeting O<\/span>ligomer P<\/span>athology of A<\/span>lpha-S<\/span>ynuclein in MSA<\/span>)<\/span><\/p>\n\n- Study drug<\/b>
Emrusolmin (anle138b, TEV-56286)<\/li>\n- Random group allocation<\/b>
(drug vs. placebo)<\/li>\n